Our Company / Alfasigma at glance
Alfasigma is one of the top 5 pharmaceutical companies in Italy, with a turnover in 2022 exceeding 1.2 billion euro. It’s a private company with more than 75% owned by the family of the founder. The Alfasigma legacy is firmly anchored in a long lasting heritage of innovation and success, beginning in 1948 in Bologna (Italy) thanks to Marino Golinelli, entrepreneur and philanthropist, who recently passed away at the age of 101.
From the beginning Alfasigma has always pursued a twofold strategy:
– internally, a strong focus on Research & Development and Manufacturing around some proprietary
molecules, some of which represent more than 50% of the sales;
– externally, developing a robust strategy of mergers and acquisitions of other Italian and international companies (Sigma Tau, Pamlabs, Sofar).
Currently Alfasigma has around 3.000 employees.
With an extensive presence in the international market, Alfasigma can count on a large number of direct branches in 17 countries, 2 Research & Development centers, 6 manufacturing plants, as well as on a network of top-level distributors which guarantee its products distribution on five continents and in more than 100 countries.
Alfasigma, leader in the gastrointestinal area, has a portfolio that ranges from prescription specialties to self-medication products, up to nutraceuticals.
millions in 2022
5 proprietary molecules
Rifaximin, Sulodexide, Carnitine, L-Methylfolate, Parnaparin
Contract Manufacturing – Business Unit